Coronavirus channel feed

GSK's Hal Bar­ron buys a $250M stake in George Scan­gos' Vir and makes a bee­line to the clin­ic with Covid-19 an­ti­bod­ies

6 years ago
Deals
R&D

Covid-19 roundup: In­ovio gets FDA green­light to en­ter hu­man tri­als; Trump push­es untest­ed malar­ia drugs again

6 years ago

Biotech ex­ecs warn that the FDA is fum­bling their re­sponse to the Covid-19 open-door promise, de­lay­ing progress

6 years ago
Bioregnum
FDA+

Ramp­ing up glob­al pro­duc­tion of remde­sivir, Gilead CEO Dan O’Day de­tails plans to dis­trib­ute 1.5M dos­es to fight Covid-19 — for free

6 years ago
Pharma

FDA re­ports short­age of se­da­tion drug used for putting Covid-19 pa­tients on ven­ti­la­tors

6 years ago
FDA+

Covid-19 roundup: Mod­er­na CEO Stéphane Ban­cel be­comes a bil­lion­aire; No­var­tis, In­cyte pitch Jakafi PhI­II to tack­le se­vere cas­es

6 years ago
R&D

Drug dis­cov­ery in the age of coro­n­avirus

6 years ago
Biotech Voices

FDA OKs a tri­al for a new Covid-19 ther­a­py af­ter an un­usu­al pub­lic­i­ty cam­paign touts its po­ten­tial — with help from Rudy Giu­liani

6 years ago
Bioregnum
R&D

Covid-19 roundup: Am­gen joins the race to de­vel­op a drug; Doc­tors, nurs­es em­ployed by Mer­ck, Lil­ly, Pfiz­er can pitch in at the front lines

6 years ago

The race to de­vel­op Covid-19 drugs and vac­cines is on — here’s what’s hap­pen­ing in the UK

6 years ago

Covid-19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

6 years ago

Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

6 years ago
FDA+

It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

6 years ago
R&D

Brii Bio gets all hands on deck for Covid-19 an­ti­body hunt, lever­ag­ing Chi­nese part­ner­s' work with re­cov­ered pa­tients

6 years ago
R&D
China

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

6 years ago

Covid-19 and weak da­ta force pipeline re­vamp at Rea­ta, but the best tri­als go for­ward — with some cre­ative adap­tions

6 years ago
R&D

Covid-19 roundup: J&J, BAR­DA set ear­ly 2021 fin­ish line for $1B vac­cine race; FDA al­lows emer­gency drug use, ahead of piv­otal da­ta

6 years ago

IL-6 to the res­cue? Sanofi, Re­gen­eron bar­rel ahead in­to an­oth­er piv­otal ef­fort test­ing Kevzara for Covid-19

6 years ago
Deals

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

6 years ago
R&D

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

6 years ago
R&D

A Sin­ga­pore VC rais­es $200M for a new round, but will Covid-19 pre­vent it from rais­ing the rest?

6 years ago
Financing

Covid-19 roundup: CDER pon­ders a move to vir­tu­al ad­comms; con­ser­v­a­tive group urges eas­i­er ac­cess to hy­drox­y­chloro­quine

6 years ago

Sanofi turns to an up­start in the mR­NA field in lat­est at­tempt to quick­ly squelch a glob­al pan­dem­ic

6 years ago
R&D

Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

6 years ago
R&D
First page Previous page 54555657585960 Next page Last page
A service from the Financial Times